“Teaming up with Roquette is another step forward in our efforts to work across our ecosystem to accelerate ‘access for all,’” said Frank Langston, Beren’s Senior Vice President of Business Strategy.

This relationship can open up expanded capabilities for us in chemistry, manufacturing, controls (CMC) management, advancing safety protocols and regulatory registration.” Beren’s research indicates incredible untapped horizons in the cyclodextrin market that enable tackling the world’s greatest health challenges. “We've been impressed by Beren's work as a Public Benefit Corporation and their innovations in manufacturing and drug development.

“Our refusal to stand still has helped us establish a leading market position and identify where the next big development in the pharma space is likely to emerge – and that’s what we see in our new relationship with Beren Therapeutics,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette. Roquette recognizes the revolutionary potential of Beren’s research to transform the market and the lives of millions of patients worldwide. LA MADELEINE, France & THOUSAND OAKS, Calif.-( BUSINESS WIRE)- Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.īeren is a vertically integrated biopharmaceutical company focused on addressing the world’s most significant health challenges.

Moss for plants download